PM
TXG icon

Prosight Management’s 10x Genomics TXG Stock Holding History

Prosight Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49,021
Closed -$953K – 59
2024
Q2 		$953K Buy
49,021
+19,021
+63% +$498K 0.29% 40
2024
Q1 		$1.13M Buy
+30,000
New +$1.32M 0.31% 37

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Prosight Management's TXG Position: Q3 2024 in Review

Prosight Management sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 49,021 shares — an estimated $953K sold.

Prosight Management first reported a position in TXG in Q1 2024 and held it in 2 quarters. The position peaked at $1.13M in Q1 2024. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

  • Prosight Management reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
  • Prosight Management sold 49,021 10x Genomics shares in Q3 2024, an estimated $953K.
  • Prosight Management first reported a position in 10x Genomics in Q1 2024 and held it in 2 quarters.
  • Prosight Management's 10x Genomics position peaked at $1.13M in Q1 2024.
  • 266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on Prosight Management's 13F filing for Q3 2024, filed 14 Nov 2024.